Cargando…

Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma

Targeted therapies, including BRAF and MEK inhibitors, are valuable treatment options for patients with unresectable or metastatic BRAF V600-mutant melanoma. With the improvement in survival seen with modern melanoma therapeutics, clinicians are learning the variable patterns associated with extende...

Descripción completa

Detalles Bibliográficos
Autores principales: Dar, Nakul, Gradecki, Sarah E., Gaughan, Elizabeth M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495986/
https://www.ncbi.nlm.nih.gov/pubmed/37706179
http://dx.doi.org/10.3389/fonc.2023.1217179
_version_ 1785105011668156416
author Dar, Nakul
Gradecki, Sarah E.
Gaughan, Elizabeth M.
author_facet Dar, Nakul
Gradecki, Sarah E.
Gaughan, Elizabeth M.
author_sort Dar, Nakul
collection PubMed
description Targeted therapies, including BRAF and MEK inhibitors, are valuable treatment options for patients with unresectable or metastatic BRAF V600-mutant melanoma. With the improvement in survival seen with modern melanoma therapeutics, clinicians are learning the variable patterns associated with extended clinical courses. Sarcoidosis is characterized by non-caseating granulomatous inflammation of unknown etiology, often presenting with cutaneous, lung, or lymph node involvement. There is a known association between sarcoidosis and melanoma, and sarcoidosis is increasingly seen and described in the setting of anti-melanoma therapy. The challenge for clinicians is to differentiate between sarcoid-related and malignancy-related findings, which may follow a variable course over years. We present two cases of BRAF and MEK inhibitor-related sarcoidosis in patients with melanoma and review the literature. The dynamic nature of the clinical and radiographic findings impacted patient management and clinical decisions for years of their treatment course.
format Online
Article
Text
id pubmed-10495986
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104959862023-09-13 Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma Dar, Nakul Gradecki, Sarah E. Gaughan, Elizabeth M. Front Oncol Oncology Targeted therapies, including BRAF and MEK inhibitors, are valuable treatment options for patients with unresectable or metastatic BRAF V600-mutant melanoma. With the improvement in survival seen with modern melanoma therapeutics, clinicians are learning the variable patterns associated with extended clinical courses. Sarcoidosis is characterized by non-caseating granulomatous inflammation of unknown etiology, often presenting with cutaneous, lung, or lymph node involvement. There is a known association between sarcoidosis and melanoma, and sarcoidosis is increasingly seen and described in the setting of anti-melanoma therapy. The challenge for clinicians is to differentiate between sarcoid-related and malignancy-related findings, which may follow a variable course over years. We present two cases of BRAF and MEK inhibitor-related sarcoidosis in patients with melanoma and review the literature. The dynamic nature of the clinical and radiographic findings impacted patient management and clinical decisions for years of their treatment course. Frontiers Media S.A. 2023-08-29 /pmc/articles/PMC10495986/ /pubmed/37706179 http://dx.doi.org/10.3389/fonc.2023.1217179 Text en Copyright © 2023 Dar, Gradecki and Gaughan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Dar, Nakul
Gradecki, Sarah E.
Gaughan, Elizabeth M.
Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
title Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
title_full Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
title_fullStr Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
title_full_unstemmed Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
title_short Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
title_sort case report: dynamic overlap of melanoma, sarcoidosis, and targeted therapy for braf-mutant melanoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495986/
https://www.ncbi.nlm.nih.gov/pubmed/37706179
http://dx.doi.org/10.3389/fonc.2023.1217179
work_keys_str_mv AT darnakul casereportdynamicoverlapofmelanomasarcoidosisandtargetedtherapyforbrafmutantmelanoma
AT gradeckisarahe casereportdynamicoverlapofmelanomasarcoidosisandtargetedtherapyforbrafmutantmelanoma
AT gaughanelizabethm casereportdynamicoverlapofmelanomasarcoidosisandtargetedtherapyforbrafmutantmelanoma